Suggested remit: To appraise the clinical and cost effectiveness of cipaglucosidase alfa with miglustat within its marketing authorisation for treating Pompe disease.
Status Awaiting development
Decision None selected
Process STA 2018

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
08 September 2021 - 06 October 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on our processes and methods, please see our CHTE processes and methods manual